CCELNYSEServices-Misc Health & Allied Services, NECFiscal year ends November 30
CRYO CELL INTERNATIONAL INC
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 9, 2026
$4.65+0.23 (+5.20%)
Close on Oct 19, 2026
- Market cap
- $37.50M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
76.6%+7.6 pts over 5 years
Operating margin
1.5%−23.1 pts over 5 years
Net margin
-7.7%−19.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -1.3% | +1.3% | +0.3% | +4.1% | |
| Gross profit | +0.6% | +3.9% | +2.4% | +4.6% | |
| Operating income | -86.1% | -50.7% | -42.5% | -16.5% | |
| Free cash flow | +45.5% | – | -8.9% | +1.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 13.0% | -75.4% | 15.3% | |
| Return on assets | -6.8% | 8.1% | -3.8% | |
| Current ratio | 0.69 | 1.13 | 0.59 | |
| Debt to equity | -0.09 | -1.07 | -0.44 | |
| Net debt to EBITDA | -3.53× | -0.94× | 5.35× | |
| Interest coverage | 0.5× | 5.0× | 0.2× | |
| Inventory turnover | 13.8× | 9.6× | 13.8× | |
| Capex to revenue | 1.5% | 0.3% | 0.7% | |
| Diluted shares | 8M | 8M | 8M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cryo Cell International generated $36.91M from operations and spent $40.86M on capital expenditure, dividends and share buybacks. 57% of that went back into the business.
Generated
$36.91M
Used
$40.86M
Capital expenditure$23.48M57%Dividends$12.92M32%Share buybacks$4.46M11%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-7.7%
×Asset turnover0.50×
×Equity multiplier-3.97×
=Return on equity, FY202515.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -7.7% | 0.50× | -3.97× | 15.3% |
| FY2024 | 1.3% | 0.49× | -5.33× | -3.3% |
| FY2023 | -30.4% | 0.48× | -10.32× | 151.7% |
| FY2022 | 9.1% | 0.48× | 47.20× | 208.4% |
| FY2021 | 7.2% | 0.54× | 70.34× | 274.3% |
| FY2020 | 11.6% | 0.70× | -9.26× | -75.4% |
| FY2019 | 7.2% | 0.74× | -5.41× | -28.9% |
| FY2018 | -2.9% | 0.87× | -3.12× | 8.0% |
| FY2017 | 9.1% | 1.17× | -1.56× | -16.6% |
| FY2016 | -5.7% | 1.18× | -1.92× | 13.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$2.43M
- Cash generatingOperating cash flow above zero$5.48M
- Return on assets improvedROA up on the prior year0.6% → -3.8%
- Earnings backed by cashOperating cash flow above net income$5.48M vs -$2.43M
- Less leverageLong-term debt to assets fell12.8% → 13.2%
- Better liquidityCurrent ratio rose0.58 → 0.59
- No dilutionShare count did not rise8M → 8M
- Gross margin improvedGross margin up on the prior year75.15% → 76.63%
- More efficientAsset turnover rose0.49 → 0.49